Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also
block the growth of the tumor by blocking blood flow to the tumor. It is not yet known
whether bevacizumab together with dasatinib are more effective than a placebo in treating
patients with recurrent or progressive high-grade glioma or glioblastoma multiforme.
PURPOSE: This randomized phase I/II trial (Phase I completed) is studying the side effects
and best dose of dasatinib when given together with bevacizumab and to see how well it works
compared to placebo in treating patients with recurrent or progressive high-grade glioma or
glioblastoma multiforme.